|
End-of-day quote
NORDIC GROWTH MARKET
2026-08-21
|
5-day change | 1st Jan Change | ||
| 0.009200 SEK | +17.95% |
|
-4.17% | +58.62% |
| 08-20 | Spermosens widens its loss slightly, patient recruitment beats expectations: CEO | FW |
| 08-20 | Spermosens AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spermosens AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 214.4 | 22.51 | 28.63 | 3.8 | 18.4 |
| Change | - | -89.5% | 27.18% | -86.73% | 384.26% |
| Enterprise Value (EV) 1 | 208.2 | 23.32 | 33.65 | 3.371 | 11.57 |
| Change | - | -88.8% | 44.32% | -89.98% | 243.11% |
| P/E | -28x | -1.69x | -2.17x | -0.25x | -1.6x |
| PBR | 9.07x | 0.76x | 2.26x | 0.14x | 0.57x |
| PEG | -0.3x | -0x | 0x | 0x | 0x |
| Capitalization / Revenue | 5,643x | - | - | - | - |
| EV / Revenue | 5,480x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -33.9x | -1.86x | -3.1x | -0.37x | -1.26x |
| EV / FCF | -12.8x | -1.12x | -1.8x | -0.3x | -1.3x |
| FCF Yield | -7.8% | -89.4% | -55.6% | -329% | -77% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.7288 | -1.101 | -0.3204 | -0.0544 | -0.003625 |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | 0.038 | - | - | - | - |
| EBITDA | - | -12.45 | -10.7 | -8.984 | -9.024 |
| EBIT 1 | -6.151 | -12.52 | -10.87 | -9.163 | -9.201 |
| Net income 1 | -6.423 | -12.65 | -12.2 | -10.2 | -9.2 |
| Net Debt 1 | -6.201 | 0.808 | 5.025 | -0.429 | -6.836 |
| Reference price 2 | 20.400000 | 1.858000 | 0.695000 | 0.013400 | 0.005800 |
| Nbr of stocks (in thousands) | 10,511 | 12,116 | 41,194 | 283,607 | 3,173,024 |
| Announcement Date | 4/14/22 | 4/14/23 | 4/18/24 | 5/26/25 | 5/28/26 |
1SEK in Million2SEK
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPERM Stock
- Valuation Spermosens AB
Select your edition
All financial news and data tailored to specific country editions
